Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345705 | 0.89 | NOTUM (0.53) | SLC6A4SLC6A3NOTUMNPY5RTRPV1 | |
| SCHEMBL3452628 | 0.87 | NOTUM (0.45) | NOTUMTSHRNPY5RALDH1A1SMN1; SMN2 | |
| SCHEMBL23380315 | 0.86 | MAPT (0.53) | SLC6A4SLC6A3NOTUMNPSR1NPY5R | |
| SCHEMBL18581257 | 0.85 | ALDH1A1 (0.46) | NOTUMTSHRALDH1A1MEN1KMT2A | |
| SCHEMBL25983414 | 0.84 | NOTUM (0.59) | NOTUMALOX5ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL25605317 | 0.82 | ALOX5 (0.39) | NOTUMALOX5TSHRNPSR1GHSR | |
| SCHEMBL29237347 | 0.82 | SLC6A2 (0.42) | SLC6A4SLC6A3NOTUMNAMPTMGLL | |
| SCHEMBL30217172 | 0.82 | SLC6A2 (0.42) | SLC6A4SLC6A3NOTUMNAMPTMGLL | |
| SCHEMBL22804336 | 0.81 | ALDH1A1 (0.49) | SLC6A4SLC6A3NAMPTALDH1A1HTT | |
| SCHEMBL17026816 | 0.81 | NOTUM (0.54) | NOTUMALOX5TRPV1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291523-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240317726-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO, INC. | 2024-09-26 | — | — | US | disclosed |
| US-11970484-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-3814331-B9 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3814331-B9 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3814331-B1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-3814331-B1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11618747-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX-FXR GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX-FXR GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| EP-3814331-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | Phenex-FXR GmbH (DE) | 2021-05-05 | — | — | EP | disclosed |
| CN-112689630-A | Novel LXR modulators with bicyclic core moieties | 菲尼克斯-FXR股份有限公司 | 2021-04-20 | — | — | CN | disclosed |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317726-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NCOA3 | SLC6A4 2320/4885SLC6A3 2749/4885NOTUM 3180/4885 |
| US-11618747-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | SLC6A4 2766/4885SLC6A3 4458/4885NOTUM 2463/4885 |
| US-12291523-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | SLC6A4 2595/4885SLC6A3 3203/4885NOTUM 2949/4885 |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | NCOR1, NCOR2, NCOA1 | SLC6A4 2024/4885SLC6A3 2237/4885NOTUM 4408/4885 |
| US-11970484-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | SLC6A4 2766/4885SLC6A3 4458/4885NOTUM 2463/4885 |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | SLC6A4 2612/4885SLC6A3 4309/4885NOTUM 2359/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | SLC6A4 2612/4885SLC6A3 4309/4885NOTUM 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.